Fenwick & West Represents Oncothyreon in $43M Public Offering

September 23, 2014

Fenwick & West LLP represented Oncothyreon Inc. (NASDAQ: ONTY) in its concurrent but separate underwritten offerings of 10,000,000 shares of its Common Stock at a price to the public of $2.00 per share and 10,000 shares of its Series A Convertible Preferred Stock at a price to the public of $2,000.00 per share. As part of the Common Stock offering, Oncothyreon also granted the underwriters a 30-day option to purchase 1,500,000 additional shares of Common Stock. The expected gross proceeds for both offerings combined is $43 million, which reflects the exercise in full of the underwriters option to purchase additional shares of Common Stock.   

Cowen and Company, LLC acted as the sole book-running manager, and H.C. Wainwright & Co., LLC acted as the co-manager.

The Fenwick transaction team included corporate attorneys Effie Toshav, James Evans, Niki Fang, Amanda Rose, Ryan McRobert and Hans Andersson.

More information about the transactions can be obtained from Oncothyreon’s website.​​